iCo Therapeutics (OTCMKTS:ICOTF) and Dr. Reddy’s Laboratories (NYSE:RDY) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, dividends and valuation.
Earnings & Valuation
This table compares iCo Therapeutics and Dr. Reddy’s Laboratories’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|iCo Therapeutics||N/A||N/A||-$1.11 million||($0.40)||-1.50|
|Dr. Reddy’s Laboratories||$2.59 billion||4.02||$236.00 million||$1.74||36.00|
This is a summary of current ratings for iCo Therapeutics and Dr. Reddy’s Laboratories, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Dr. Reddy’s Laboratories||0||1||2||0||2.67|
Dr. Reddy’s Laboratories has a consensus target price of $71.71, suggesting a potential upside of 14.47%. Given Dr. Reddy’s Laboratories’ higher probable upside, analysts plainly believe Dr. Reddy’s Laboratories is more favorable than iCo Therapeutics.
This table compares iCo Therapeutics and Dr. Reddy’s Laboratories’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Dr. Reddy’s Laboratories||10.51%||14.84%||9.73%|
Insider and Institutional Ownership
10.2% of Dr. Reddy’s Laboratories shares are held by institutional investors. 2.0% of Dr. Reddy’s Laboratories shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Volatility & Risk
iCo Therapeutics has a beta of 2.03, indicating that its stock price is 103% more volatile than the S&P 500. Comparatively, Dr. Reddy’s Laboratories has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500.
Dr. Reddy’s Laboratories beats iCo Therapeutics on 11 of the 12 factors compared between the two stocks.
iCo Therapeutics Company Profile
Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada.
Dr. Reddy’s Laboratories Company Profile
Dr. Reddy’s Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services & Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research and development of differentiated formulations. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.
Receive News & Ratings for iCo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.